



HAL
open science

Sumoylation and cell signaling

Artemisia M Andreou, Nektarios Tavernarakis

► **To cite this version:**

Artemisia M Andreou, Nektarios Tavernarakis. Sumoylation and cell signaling. *Biotechnology Journal*, 2009, 4 (12), pp.1740. 10.1002/biot.200900219 . hal-00540528

HAL Id: hal-00540528

<https://hal.science/hal-00540528>

Submitted on 27 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Sumoylation and cell signaling

Journal:	<i>Biotechnology Journal</i>
Manuscript ID:	biot.200900219.R1
Wiley - Manuscript type:	Review
Date Submitted by the Author:	12-Oct-2009
Complete List of Authors:	Andreou, Artemisia; Foundation for Research and Technology-Hellas, Institute of Molecular Biology and Biotechnology Tavernarakis, Nektarios; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology - Hellas
Keywords:	SUMO, signaling pathways, stress



1
2
3 Review

4
5 **SUMOylation and cell signalling**

6
7 Artemisia M. Andreou and Nektarios Tavernarakis

8
9 Institute of Molecular Biology and Biotechnology, Foundation for Research and
10
11 Technology - Hellas, Heraklion, Crete, Greece

12
13 **Correspondence:** Dr. Nektarios Tavernarakis, Institute of Molecular Biology and
14
15 Biotechnology, Foundation for Research and Technology - Hellas, N. Plastira 100,
16
17 Vassilika Vouton, PO Box 1385, Heraklion 70013, Crete, Greece

18
19 **E-mail:** tavernarakis@imbb.forth.gr

20
21 **Fax:** +30-2810-391067

22
23 **Keywords:** Post-translational modification / Signalling pathways / Stress /
24
25 SUMOylation

26
27 **Abbreviations:** **DRP-1**, dynamin-related protein 1; **HSF1**, heat shock factor 1;

28
29 **MAPL**, mitochondrial-anchored protein ligase; **PIAS**, protein inhibitors of activated
30
31 STAT; **PML**, promyelocytic leukaemia protein; **pRB**, retinoblastoma protein;

32
33 **SENP**, sentrin-specific protease; **shRNA**, short hairpin RNA; **SUMO**, small ubiquitin-
34
35 related modifier; **Ubc9**, ubiquitin-like protein SUMO-1-conjugating enzyme 9

36
37 SUMOylation is a highly transient post-translational protein modification. Attachment
38
39 of SUMO to target proteins occurs via a number of specific activating and ligating
40
41 enzymes that form the SUMO-substrate complex, and other SUMO-specific
42
43 proteases that cleave the covalent bond, thus leaving both SUMO and target protein
44
45 free for the next round of modification. SUMO modification has major effects on
46
47 numerous aspects of substrate function, including subcellular localisation, regulation
48
49 of their target genes, and interactions with other molecules. The modified SUMO-
50
51 protein complex is a very transient state, and it thus facilitates rapid response and
52
53 actions by the cell, when needed. Like phosphorylation, acetylation and
54
55 ubiquitination, SUMOylation has been associated with a number of cellular
56
57 processes. In addition to its nuclear role, important sides of mitochondrial activity,
58
59
60

1
2
3 stress response signalling and the decision of cells to undergo senescence or
4
5 apoptosis, have now been shown to involve the SUMO pathway. With ever
6
7 increasing numbers of reports linking SUMO to human disease, like
8
9 neurodegeneration and cancer metastasis, it is highly likely that novel and equally
10
11 important functions of components of the SUMOylation process in cell signalling
12
13 pathways will be elucidated in the near future.
14
15
16
17

18 **1 Introduction**

20
21
22 Transient post-translational modifications like acetylation, phosphorylation and
23
24 ubiquitination are a fast and very efficient way for the cell to respond to intra- and
25
26 extracellular stimuli, and are thus favoured in cell signalling cascades. A more
27
28 recently identified transient protein modification is the attachment of a SUMO
29
30 peptide, the process of which is often referred to as SUMOylation. This has also
31
32 been shown to occur in signalling pathways, initially within the nucleus and, more
33
34 recently, also in other parts of the cell. SUMO attachment has been implicated in a
35
36 number of cell processes, such as transcription, nuclear transport, DNA repair,
37
38 mitochondrial activity, plasma membrane ion channels, cell cycle and chromatin
39
40 structure. Although its function is as diverse as its substrates, one generalisation
41
42 could be that modification of a protein substrate by SUMO alters its interactions with
43
44 other protein and DNA molecules. At any given time, only a very small amount of
45
46 substrate is modified, usually around 1%. This may be one reason why SUMO and
47
48 the modified forms of substrate proteins were only discovered recently. Since its
49
50 identification, however, a great many proteins that are modified by SUMO species
51
52 and an equally great number of pathways in which SUMO partakes are now being
53
54 revealed, and the various effects of the modification are beginning to be elucidated.
55
56
57
58
59
60

2 The SUMO modification pathway

1
2
3
4
5 Originally reported just over a decade ago as a protein related to Ubiquitin, the small
6 ubiquitin-related modifier (SUMO) has been since shown to be present in all
7 metazoans and take part in a number of diverse cellular functions, the number of
8 which is still extending [1]. Although SUMO only shares 18% of overall sequence
9 identity with ubiquitin, the general structure fold is conserved, where the C terminus
10 of SUMO is almost super-imposable on the equivalent region of ubiquitin [2, 3].
11

12 SUMO proteins have a distinct overall surface charge distribution compared to
13 ubiquitin, and the function of SUMO modification is completely different, and
14 sometimes counteractive to the ubiquitin pathway. SUMO can occupy available
15 lysine residues and inhibit ubiquitin attachment, thus protecting proteins from
16 breakdown, or it can promote proteasome-mediated degradation, possibly by
17 recruiting and/or regulating enzymes that control degradation.
18

19 The SUMO protein sequence is around 100 amino acids, with a molecular mass of
20 ~11 kDa; it is highly conserved in all eukaryotic cells, and is present in all tissues
21 and developmental stages of higher organisms. It has been shown to be essential
22 for cell viability both at the organism level and in cells in culture [4]. Different
23 organisms contain different numbers of SUMO species, with a single SUMO present
24 in yeast (*Smt3p*) [5], *Drosophila* (*SMT3*) [6], and *Caenorhabditis elegans* (*smo-1*)
25 [7], and four SUMO peptides in mammals, termed SUMO-1, SUMO-2, SUMO-3 and
26 SUMO-4 [8–11]. SUMO-4 is the most recently identified gene and has an 86%
27 similarity to SUMO-2. Its mRNA transcripts are mainly present in kidney, lymph
28 system and spleen, but show limited expression compared to the other SUMO
29 species [8]. Since no native SUMO-4 protein has yet been detected in any tissue, it
30 has been suggested that SUMO-4 might be an expressed pseudogene [12]. In
31 addition, a proline in a position at its C terminus instead of a glutamine results in
32 resistance of SUMO-4 to hydrolysis by SUMO-specific proteases and it can thus not
33 be processed to a mature form capable for conjugation [13]. SUMO-1 shares 50%
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sequence identity with SUMO-2 and -3, while SUMO-2/3 share a 95% identity. Also,
4
5 SUMO-2/3 possess consensus SUMOylation sites at their N-terminal tails that allow
6
7 formation of poly-SUMO chains, in contrast to SUMO-1, where these sites are
8
9 absent, along with the capacity for chain formation [14]. The differences between
10
11 the isoforms also translate to functional activity, as the function of SUMO-2/3 is
12
13 almost indistinct, whereas SUMO-1 has a dissimilar function. In the case of intrinsic
14
15 transcriptional repression ability, for example, SUMO-2 and -3 show stronger
16
17 inhibitory activity compared to SUMO-1, the activity of which appears weaker [15,
18
19 16]. Furthermore, while there are pools of free SUMO-2/3 available within cells,
20
21 SUMO-1 is rarely found unattached [17]. Certain proteins show a preference in
22
23 conjugation to either SUMO-1 or SUMO-2/3, but others can be modified equally well
24
25 by both SUMO species.
26
27

28 Attachment of SUMO to target proteins takes place using a similar mechanism to
29
30 ubiquitin attachment, where the enzymes that catalyse SUMO complex formation
31
32 are analogous to the ubiquitin pathway. SUMO modification enzymes are specific
33
34 for this peptide and not interchangeable with the equivalent for ubiquitination.
35
36 SUMOylation occurs via the formation of an isopeptide bond between the glycine
37
38 residue at the C-terminal end of SUMO to the ϵ -amino group of an internal lysine
39
40 residue within the substrate [18]. The SUMO peptide is initially translated as a
41
42 precursor, with a short sequence extending past a conserved GG motif that defines
43
44 the carboxyl end of the mature protein. Proteolytic cleavage of this sequence
45
46 converts SUMO to its mature form. SUMO-specific peptidases, for example
47
48 members of the sentrin-specific protease (SENPs) family, catalyse this step. SUMO-
49
50 activating enzymes, also called E1, activate the mature SUMO in an ATP-
51
52 dependent reaction. Active SUMO is then transferred onto the E2 SUMO-
53
54 conjugating enzyme Ubc9 [19–21]. Conjugation of SUMO to target proteins occurs
55
56 through Ubc9 with the aid of an E3 ligase [22, 23] (Fig. 1). Substrate specificity for
57
58 SUMO is conferred by both Ubc9 and various E3 ligases, the former by forming the
59
60

1
2
3 covalent attachment of SUMO to its targets, while the latter probably interacts with
4
5 other areas of the substrate and provides more specificity [24].
6

7 ((Fig. 1))
8

9
10 SUMO attachment is a reversible and highly transient modification. The same
11
12 enzymes that facilitate the initial maturation of SUMO molecules also catalyse the
13
14 cleavage from their substrates. Six human SENP family proteins, SENPs 1–3 and
15
16 5–7 have been shown to be SUMO-specific proteases [25]. Unlike the enzymes
17
18 catalysing SUMO attachment, SUMO proteases show little similarity to the
19
20 equivalent enzymes in the ubiquitin pathway, but appear closely related to viral
21
22 proteases [26]. The differential subcellular localisation of the SENP proteins, most
23
24 likely dictated by non-conserved N-terminal sequences, is thought to provide the
25
26 specificity for the SUMO-substrate complexes they regulate [27, 28]. SENP1 is
27
28 localised mainly in the nucleus with little, albeit persistent, cytoplasmic presence [29,
29
30 30]; SENP2 is associated with the nuclear pore [31]; SENP3 and SENP5 are
31
32 nucleolar [32], while separate reports place SENP6 in both the nucleoplasm and the
33
34 cytosol [33, 34]. Although the SUMO isoforms and the SUMOylation target proteins
35
36 described so far are predominantly nuclear, increasing numbers of enzymes of the
37
38 SUMO conjugation pathway as well as SUMO-target complexes are being identified
39
40 in other parts of the cell, like the cytosol, the plasma membrane and the
41
42 mitochondria [35–37]. Specificity in SUMO complex targeting may be achieved
43
44 through the subcellular location of each protease [38].
45
46
47

48
49 A short amino acid sequence motif within the target protein frequently serves as a
50
51 recognition site for SUMO attachment. This recognition site is conserved and
52
53 presents the consensus sequence ψ KXE/D [39, 40], where ψ is a large hydrophobic
54
55 amino acid, like leucine, isoleucine or valine; K is the lysine residue at which the
56
57 attachment takes place, and X is any amino acid followed by a glutamic (E) or
58
59 aspartic (D) acid. At the same time this sequence was identified as the SUMOylation
60
consensus, independent studies pinpointed it as a SUMOylation-dependent

1
2
3 transcriptional inhibitory motif in transcription factors [41, 42]. A number of
4
5 alternative SUMO modification sequences have also been described, in which for
6
7 example the amino acid before the lysine can be a different one from the three
8
9 consensus residues. Furthermore, SUMOylated proteins have been described that
10
11 either do not contain the consensus site, use a different motif for SUMO conjugation
12
13 [16], or maintain SUMOylation after the recognition site has been mutated. More
14
15 extensive SUMO conjugation motifs have also been described; it has been
16
17 suggested that acidic residues downstream of the core SUMOylation motif have a
18
19 role in enhancing specificity for substrates [43]. SUMO attachment sites are often
20
21 found in the vicinity of activation or repression domains of target proteins, as for
22
23 example in Msx1 [44].
24
25

26
27 SUMOylation alters the relations of the modified target with other macromolecules,
28
29 through providing novel interaction surfaces. Thus, besides the sites for SUMO
30
31 conjugation, other sequences have been identified that mediate interactions
32
33 between SUMOylated complexes and their protein partners. A conserved SUMO-
34
35 interacting motif (SIM) has been found on proteins that associate with SUMO-
36
37 conjugated moieties, including the promyelocytic leukaemia protein (PML) and
38
39 members of the protein inhibitors of activated STAT (PIAS) family [16, 45]. Mutation
40
41 of these sites abolishes their interaction with the SUMO-target complex. In addition,
42
43 the surface of SUMO that the SIM of interacting proteins binds is an essential region
44
45 required for transcriptional repression when SUMO is recruited to promoter regions
46
47 [15, 46].
48
49
50
51
52

53 **3 Links with phosphorylation/acetylation/ubiquitination**

54
55
56

57
58 Other post-translational protein modifications have been associated with the SUMO
59
60 pathway. The availability of certain proteins for SUMOylation has been shown to be
dependent on their phosphorylation status, like for example GATA-1 (GATA-binding

1
2
3 protein 1, globin transcription factor 1), myocyte-specific enhancer factor 2A
4
5 (MEF2A), Smad nuclear interacting protein 1 (SNIP-1), and heat shock factors
6
7 HSF1 and HSF4b. The HSF1 factor, which is deficient in its phosphorylation
8
9 capacity, cannot become modified by SUMO, as this protein needs to undergo a
10
11 conformational change, mediated by phosphorylation of a serine residue, to allow
12
13 SUMO attachment [47]. Moreover, the phosphorylation of these heat shock factors
14
15 is heat inducible and may be directly associated with the inducible SUMOylation of
16
17 HSF1 [48]. A phosphorylation-dependent SUMOylation motif (PDSM), which greatly
18
19 resembles an extended consensus SUMO attachment site, ψ KxExxSP, has been
20
21 described for such proteins [49]. Furthermore, histone deacetylases, including
22
23 HDAC2 and HDAC6, have been shown to preferentially interact with SUMO-
24
25 modified substrates [50, 51]. It has been suggested that deacetylation of histones by
26
27 HDAC enzymes may make more lysine residues available for SUMOylation [52]. A
28
29 SUMOylation switch based on acetylation/deacetylation has been described in the
30
31 p53-HIC1-SIRT1 regulatory loop [53]. Hypermethylated in cancer 1 (HIC1), a protein
32
33 involved in the p53 tumour suppression pathway, has been shown to be both
34
35 SUMOylated and acetylated, possibly on the same lysine residue, as lysine mutants
36
37 that are SUMOylation deficient show much lower levels of acetylation compared to
38
39 the wild-type protein. Deacetylases with roles in the p53 pathway, sirtuin 1 (SIRT1),
40
41 a NAD-dependent deacetylase, and HDAC4, appear to promote deacetylation and
42
43 SUMOylation, respectively [53]. Increased SUMOylation of H4 correlates with
44
45 decreased acetylation of the gene when Ubc9 is targeted to the promoter region
46
47 [54]. An association between SUMOylation and the ubiquitin pathway is perhaps not
48
49 surprising due to the close relation between the two proteins. SUMO-1
50
51 overexpression results in reduced levels of p63 [55]. Since mutating the SUMO
52
53 acceptor sites of p63 appears not to have any effect on protein levels, this down-
54
55 regulation of the protein is not dependent on its own SUMOylation state and is more
56
57 likely to result from changes in the SUMOylation of other regulatory proteins [56]. In
58
59
60

1
2
3 the case of Smad4, when its SUMO attachment sites are mutated, the lysine mutant
4 displays increased stability compared to wild-type protein due to reduced poly-
5 ubiquitination [57]. Because SUMO peptides can use the same lysine residues as
6 ubiquitin, SUMOylation of a substrate protein may lead to protection from
7 degradation through the ubiquitin pathway. However, at the same time, if these sites
8 are disrupted, ubiquitin attachment may also be hindered, and thus lead to
9 increased stability. This effect is different to impaired SUMOylation due to increased
10 activity of SENPs, where the lysine residues of the SUMO sites are still intact and
11 available for interaction with ubiquitin. One of the rare cases where SUMOylation
12 promotes protein catabolism involves the promyelocytic leukaemia gene product
13 (PML) that concentrates in nuclear bodies, and the product of its fusion to the
14 retinoic acid receptor α (PML-RAR α) that occurs after a chromosomal translocation
15 in patients with acute promyelocytic leukaemia [58–61]. Induction of SUMO
16 modification of PML and PML-RAR α upon arsenic treatment recruits a ubiquitin E3
17 ligase (ring finger protein 4, RNF4) onto the nuclear bodies, where these proteins
18 reside. RNF4, a small nuclear protein, contains a number of SUMO-interacting
19 motifs in its sequence and preferentially interacts with PML and PML-RAR α proteins
20 modified by poly-SUMO-2 chains. Along with RNF4, SUMO isoforms, ubiquitin, the
21 20S proteasome and specific transcription factors are also recruited to PML nuclear
22 bodies, and PML and PML-RAR α are degraded through SUMOylation-dependent
23 ubiquitination [62, 63].
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **4 Involvement of SUMO in different cellular pathways**

52
53
54
55 SUMO modification has been frequently associated with transcriptional regulation,
56 mainly through promoting transcriptional repression, but also in some cases aiding
57 activation, depending on the specific substrate and biochemical pathway [64]. In
58 fact, the majority of SUMOylation targets reported to date have been sequence-
59
60

1
2
3 specific transcription factors and the essential role of the SUMO pathway has been
4
5 conclusively supported in all aspects of transcription regulation, from promoter
6
7 binding to recruitment of co-factors [18, 52, 65]. Nevertheless, it would be fair to say
8
9 that the function of SUMOylation extends a lot further than transcription control and
10
11 covers a great variety of cellular processes, including genome integrity, DNA repair,
12
13 protein trafficking, activity of voltage-gated ion channels and protein stability [4, 37].
14
15 In addition, since this review appears in this special issue of the Biotechnology
16
17 Journal, it seems important to mention the applications that SUMO has had in the
18
19 field of Biotechnology. N-terminal fusion of proteins, even ones that are difficult to
20
21 express, to native and truncated forms of SUMO results in greatly increased
22
23 expression levels and improved solubility, both in bacterial [66–69] and eukaryotic
24
25 expression systems [70–72]. The SUMO part of the fusion protein can be retained
26
27 and removed at will, through the use of appropriate SUMO proteases, thus making it
28
29 possible to closely regulate the activity of enzymes or toxic proteins.
30
31
32
33 Most recently, important roles for the SUMO pathway have been elucidated in areas
34
35 that may provide stronger links between SUMOylation and the process of aging,
36
37 including the activity of the mitochondria, the major tumour suppressor pathways
38
39 and signalling pathways leading to senescence. Further support to the significance
40
41 of this modification for maintaining normal cell and tissue homeostasis is provided
42
43 by the fact that defects in components of the SUMOylation pathway, either
44
45 individually or synergistically, have been linked to an increasing number of disease
46
47 phenotypes in humans [73–79]. Below, we present these areas in more detail.
48
49
50
51
52

53 **5 SUMO and mitochondrial activity**

54
55
56

57 Mitochondria have been traditionally called the powerhouses of the cell as they
58
59 provide most of the energy (in the form of ATP) needed for cell metabolism. The
60
morphology of the mitochondria is crucial to their normal function and mutations that

1
2
3 affect the shape of these organelles have been linked to problematic cell
4
5 homeostasis and neurodegenerative conditions [80]. Normal mitochondrial
6
7 morphology is maintained through a balance between the processes of fusion and
8
9 fission, and these processes are essential for the maintenance of healthy cell
10
11 metabolism and homeostasis. Mitochondrial fusion forms a network of
12
13 interconnected organelles that maintains mitochondrial DNA and facilitates transfer
14
15 of electron potential between different areas of the cell [81]. Mitochondrial fission
16
17 ensures equal division of material between daughter cells after mitosis and provides
18
19 the cell with extra energy under specific circumstances, as for example during
20
21 spermatogenesis in *Drosophila* [82] and during the early stages of apoptosis [83].
22
23 The idea that mitochondrial activity and the regulation of the equilibrium between
24
25 fission and fusion in response to signalling cascades is maintained by dynamic post-
26
27 translational modifications has been positively regarded for a while, as transient
28
29 protein modifications present perhaps the easiest way to control systems that go
30
31 through rapidly changing states.
32
33
34
35 The first line of evidence that SUMOylation is involved in mitochondrial function
36
37 came 5 years ago, when mitochondrial dynamin-related protein 1 (DRP-1) was
38
39 reported to interact in a yeast two-hybrid screen with Ubc9 and SUMO-1 [84]. DRP-
40
41 1 is a large dynamin-like GTPase that is transported from the cytosol to the
42
43 mitochondrial membrane during the process of mitochondrial fission and functions to
44
45 facilitate the fragmentation of the mitochondria. Fluorescence immunostaining
46
47 experiments showed SUMO-1 signals to co-localise with DRP-1 at the site of
48
49 mitochondrial fission, while overexpression of SUMO-1 protects DRP-1 from
50
51 degradation (as does the presence of *N*-ethylmaleimide, a SUMO-1 hydrolase
52
53 inhibitor) and induces fragmentation of mitochondria, as shown by the specific
54
55 organelle morphology [84]. More recent studies have conclusively demonstrated the
56
57 modification of DRP-1 by SUMO-1 and identified the site of interaction at specific
58
59 residues [85]. Furthermore, high numbers of SUMO-1-conjugated proteins were
60

1
2
3 identified in the mitochondrial part after cell fractionation, thereby suggesting that
4
5 SUMOylation is important in various aspects of mitochondrial activity.

6
7
8 In more recent years, the specific enzymes that catalyse the SUMO conjugation/ de-
9
10 conjugation cycle of DRP-1 have been identified. SENP5 has been shown to be
11
12 able to hydrolyse the SUMO-1/DRP-1 conjugate [86], while the mitochondrial-
13
14 anchored protein ligase (MAPL) has been identified as the complex-specific E3
15
16 ligase [35]. SENP5 has been shown to be essential for normal mitochondrial
17
18 morphology and function, as both overexpression and silencing of this protease
19
20 have profound mitochondrial phenotypes. Overexpression of SENP5 rescues the
21
22 mitochondrial fragmentation caused by SUMO-1 up-regulation, while blocking of
23
24 SENP5 by short hairpin RNA (shRNA) results in extensive mitochondrial
25
26 fragmentation and much lower rates of mitochondrial fusion compared to control
27
28 cells. In addition to problematic mitochondrial morphology, shRNA-SENP5 cells
29
30 show a significant rise in the production of reactive oxygen species (ROS), and it
31
32 has been suggested that this high concentration of free radicals may actually be the
33
34 cause of the decrease of mitochondrial fusion in these cells [86]. When DRP-1 is
35
36 down-regulated in these cells, ROS production returns to normal levels,
37
38 fragmentation is hindered and mitochondria appear fused into a network. Besides
39
40 DRP-1 regulation, SENP5 showed a broader specificity for a number of
41
42 mitochondrial SUMO-conjugated proteins, further supporting its importance in
43
44 mitochondrial function. The protective role of SENP5 in mitochondrial morphology
45
46 and metabolic status is specific, as another member of the SUMO protease family,
47
48 SENP2, has no effect on mitochondria morphology or substrates [86].
49
50
51
52
53 MAPL has been identified as a protein ligase that contains a RING domain, is
54
55 anchored to the mitochondrial outer membrane and has a role in mitochondrial
56
57 fragmentation [87]. Recently, it has been shown that MAPL is a SUMO-specific E3
58
59 ligase and the first mitochondrial one [35]. Experiments with synthetic peptides as
60
well as native mitochondrial SUMO targets support this role. Down-regulation of

1
2
3 MAPL via shRNA leads to a significant decrease in SUMOylation, while there is
4
5 almost no effect on the ubiquitination state of the cells, unless enzyme
6
7 concentrations reached very high levels that are believed not to be biologically
8
9 relevant. Therefore, MAPL specifically and preferentially catalyses SUMO
10
11 conjugation and is not a ubiquitin ligase [35]. Furthermore, shRNA against MAPL
12
13 hinders global cell SUMOylation, but the mitochondrial fraction of the cells is the
14
15 mostly affected compared to the nuclear and cytosolic parts, suggesting that many
16
17 of the SUMO target proteins that MAPL specifically modifies may be present in
18
19 mitochondria. More data on the specific SUMOylated proteins that are affected by
20
21 such global down-regulation of the SUMO pathway through MAPL are needed to
22
23 further elucidate the function of SUMOylation in the mitochondria.
24
25
26
27
28

29 **6 SUMO and environmental stress**

30
31
32
33 SUMO modification has been shown to be susceptible to environmental effects,
34
35 especially different types of cellular stress [88]. Such factors include oxidative
36
37 stress, osmotic stress, heat shock, exposure to ethanol and viral infection [17, 89–
38
39 92].
40

41
42 Initially SUMO-2 and -3 were mainly associated with cellular responses to stress,
43
44 with reports that showed altered substrate interactions after stress signals [93, 94]
45
46 and very recent experiments showing that they are essential for cell survival after
47
48 heat shock [95]. SUMO-1 has now also been demonstrated to play a role in stress
49
50 response as its expression increases during hypoxia [96]. Exposure of cells to
51
52 oxidative stress led to modification of the targeting patterns of the SUMO peptides,
53
54 which were de-conjugated from original complexes and re-distributed to new
55
56 substrates, including anti-oxidant proteins and proteins involved in signalling during
57
58 DNA damage. Reports on the response of the SUMO pathway to oxidative stress
59
60 have been contradictory, with some suggesting stress results in an increase in

1
2
3 SUMO modification of target proteins, while others demonstrate a disappearance of
4 SUMO-conjugated species under similar conditions [94, 97]. Experimental design
5 may play a role in these results, but since SUMOylation has been associated with a
6 variety of diverse cellular functions, it may also be that different mechanisms of
7 conjugation and de-conjugation are in place for different signalling and transcription
8 regulation pathways. For example, inducing oxidative stress by treating cells with
9 hydrogen peroxide resulted in increased levels of SUMO-2/3-modified p53, while
10 levels of p53/SUMO-1 conjugates appeared unaffected [98]. The observation that
11 substrate proteins are not all affected at the same time or with the same speed may
12 support this theory [88]. Mimicking oxidative stress conditions in cell-based assays
13 with low, and thus perhaps more physiologically relevant, concentrations of reactive
14 oxidative species inhibits the activity of SUMO-conjugating enzymes. This leads to a
15 general decrease in SUMOylation of substrate proteins, including essential
16 transcription factors [88]. This effect was shown to be specific to the SUMO
17 modification process, since the ubiquitin pathway was not affected. Such stress can
18 occur *in vivo* after exposure to UV, ionising radiation, chemotherapeutic agents and
19 hyperthermia [99]. Cellular responses to elevated temperature have also been
20 linked to SUMOylation through the modification by SUMO of HSF1, as mentioned
21 before [47].

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 Another likely influence on the SUMO process is viral infection [100, 101]. Gam-1, a
45 viral protein from an avian adenovirus, can target E1 and E2 SUMO ligases for
46 degradation and thus inhibits cellular levels of SUMO modification [100]. Down-
47 regulation and loss of SUMOylated substrates leads to an up-regulation of cellular
48 transcription and is thought to enhance viral replication. This association is made
49 perhaps more interesting by the fact that, as mentioned earlier, the SUMO-specific
50 hydrolases are much more closely related to viral proteases than to the
51 corresponding enzymes in the ubiquitin pathway [102].
52
53
54
55
56
57
58
59
60

7 SUMO in cellular senescence and ageing

A number of senescence-associated proteins have been identified as targets for SUMO attachment and, more recently, SUMO peptides and enzymes that participate in the SUMO pathway have been linked with the process of senescence. The SUMO isoforms, a SUMO-specific E3 ligase and a SUMO hydrolase have been shown to have either positive or negative effects on the induction of cellular senescence (Fig. 2). In addition, elevated numbers of SUMOylated proteins have been shown to accumulate in senescent cells compared to normal replicating cells [103], while levels of SUMO isoforms and associated enzymes appear to decrease with age in a different tissue type [104].

((Fig. 2))

The different substrate specificity frequently observed for SUMO-1 and SUMO-2/3 species means they can take part in different cascades within the cell, even within the same greater pathway. Overexpression of SUMO-2/3 in cultured cells has been shown to induce premature senescence, observed by slow cell growth and early growth arrest of these cells [98], while SUMO-1 up-regulation does not appear to affect the process of cellular senescence [105]. This is perhaps not surprising, considering that SUMO-2/3 is thought to be the isoform(s) mainly and most frequently associated with the response to stress. However, it is interesting that under normal conditions SUMO-1 appears mainly conjugated to target proteins within the cells, while unconjugated pools of SUMO-2/3 species are abundant and available to be used as required.

When cells experience some form of stress, the p21/p53 and p16/retinoblastoma protein (pRB) response pathways are usually activated [106, 107]. Various genes that have been associated with the induction of senescence have been shown to be part of either the p53 or pRB pathways [108]. The major proteins in these signalling cascades, p53 and pRB, greatly influence the cell's response to the stress factor(s),

1
2
3 *i.e.* if a cell will enter senescence or undergo apoptosis, as both mechanisms are
4 used to manage unsolicited cell growth [109]. p53 and pRB can inhibit unsolicited
5 cell growth through pathways regulated by post-translational modifications, including
6 phosphorylation, acetylation, ubiquitination and SUMOylation, as both proteins are
7 substrates for SUMO-1 and SUMO-2/3 modification [110–113]. SUMO-1 attachment
8 promotes gene transactivation by p53, as shown by up-regulation of p21
9 expression, a p53 target gene [98]. Moreover, components of the SUMO pathway
10 control pRB repression of E2F-regulated target genes [114]. pRB is normally de-
11 SUMOylated by E1A, a viral oncoprotein [111]; it has been suggested that this may
12 be a strategy used by viruses to suppress cell senescence. Overexpression of
13 SUMO-2/3 surpasses this de-SUMOylation, leaving pRB-SUMO-2/3 conjugates free
14 to stimulate senescence [98].

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
RNA interference on p53 and pRB cancels the senescence phenotype of SUMO-
2/3-overexpressing cells, thus supporting the idea that the effect of SUMO-2/3
modification on senescence occurs via p53- and pRB-mediated pathways [98]. p53-
induced up-regulation of p21 is a known pathway for activation of senescence [115].
During SUMO-2/3 overexpression, the transcriptional activity of p53 is significantly
enhanced and p21 is clearly up-regulated; however, the levels of p53 protein remain
unchanged. Since p21 is under the transcriptional control of p53, this increase in
p21 protein levels may be due to the altered SUMOylation state of p53, modified by
SUMO-2/3 [98].

During replicative senescence the levels of endogenous PIASy, a member of the
PIAS protein family of SUMO E3 ligases [116], are significantly increased compared
to presenescent cells, as are levels of hyper-sumoylated proteins [114]. No other
member of the PIAS protein family appears to have similar activity. High levels of
PIASy can result in either cellular senescence or apoptosis, depending on the state
of p53 and pRB within the cell. The E3 ligase activity of PIASy is essential for
senescence stimulation and mutation of the ligase active site on the protein

1
2
3 abolishes the effect. The E6 oncoprotein inhibits the SUMO ligase activity of PIASy
4 and blocks induction of senescence [114]. Interestingly, an extended lifespan is
5 observed in cells that overexpress mutant forms of PIASy with an inactive E3 ligase
6 site. Mouse embryo fibroblasts that are deficient in PIASy show a significant delay in
7 the onset of senescence after appropriate signalling. Even after induction of p53
8 expression by a pro-senescence signal, for example through oncogenic RAS, p53-
9 target genes p21 and murine double minute 2 (MDM2) are not up-regulated in the
10 absence of PIASy. In parallel, PIASy can induce p53-dependent apoptosis during
11 pRB deficiency; inactivation of pRB by hyper-phosphorylation is not enough to give
12 similar results and the effect of PIASy is not there when pRB is present, even in an
13 (as far as we know) inactive state [114]. The different cellular responses to PIASy,
14 depending on the pRB status, suggest a possible role for PIASy as one of the
15 factors influencing the cell's decision to undergo senescence or apoptosis. It might
16 be that PIASy is involved in altering the binding affinity between pRB and its co-
17 factors, through pRB SUMOylation. It has been suggested that hypophosphorylated
18 pRB enlists its co-repressors together with components of the SUMO pathway to the
19 site of genes promoting proliferation. A number of these co-factors could be
20 themselves targets of SUMOylation and these interactions could stabilise the pRB
21 repressor complex. Also, as it has been shown that SUMO attachment increases
22 affinity between protein partners [117], the presence of SUMO-modified pRB
23 repressor group on DNA could provide a high affinity site for the recruitment of
24 proteins involved in chromatin remodelling and reorganisation [103]. This process
25 could ultimately lead to the silencing of genes involved, also facilitated by the activity
26 of histones, which are substrates for SUMOylation and have major roles in
27 transcriptional repression in their modified state [54, 118].
28
29 Senescence may also be induced by down-regulation of a number of SUMO
30 proteases of the SENP family. SUMO proteases may thus be required for the
31 proliferation of normal human cells and have important roles in age-related
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 phenotypes. After many cell passages, when human fibroblasts undergo replicative
4 senescence, SUMO-containing PML bodies accumulate in the nucleus; this effect is
5 also seen when SUMO proteases Senp1, Senp2 and Senp7 are repressed.
6
7

8
9 Particularly Senp1 deficiency triggers premature senescence through the p53
10 signalling pathway [119], as the p53 pathway needs to be intact for the full result of
11 Senp down-regulation to be exerted. It is thus very likely that Senp1 has a role in
12 maintaining the balance in the cell after exposure to stress and perhaps preventing
13 premature senescence.
14
15
16
17
18
19

20 21 22 **8 SUMO in human disease**

23
24
25
26
27 Disturbance of the SUMO modification pathway has recently been associated with a
28 number of disease phenotypes in humans. Induction of SUMOylation has been
29 shown for cerebral ischaemia and it has been suggested that this process may have
30 a role in defining the outcome of neurons exposed to such conditions [120]. Other
31 neurodegenerative diseases have been implicated in the SUMO pathway, including
32 multiple system atrophy and Huntington's disease (HD), where SUMO peptides
33 have been shown to localise within the protein aggregates characteristic for these
34 conditions. In HD, SUMO modification of mutant huntingtin, which contains
35 polyglutamine repeats, significantly inhibits its aggregation and promotes cell death
36 [121]. This process is facilitated by Rhes (Ras homologue enriched in striatum), a
37 small guanine-binding protein that shows E3 ligase activity and greatly enhances
38 SUMOylation of mutant huntingtin and other proteins [121, 122]. Kennedy disease,
39 or spinal and bulbar muscular atrophy, is also characterised by a polyglutamine
40 expansion in the N terminus of the androgen receptor. Recent experiments have
41 shown that SUMOylation hinders aggregation of these mutated protein forms, in a
42 mechanism that is independent on androgen receptor transcription regulation [123].
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The Parkin protein also appears to have a role in regulating the turnover of an E3

1
2
3 SUMO ligase [124]. These findings strongly suggest that the SUMO pathway may
4
5 have a protective role against neurodegeneration. Furthermore, compromised
6
7 SUMOylation has been linked to some cancers, through regulation by SUMO of
8
9 nuclear receptor-mediated gene expression, for example the androgen and
10
11 estrogen receptors with roles in prostate and breast cancer, respectively [42, 125].
12
13 The regulation of a number of other genes with roles in cancer development has
14
15 been linked to SUMOylation [78], and a role for SUMO modification in cancer
16
17 metastasis has been suggested through association of the SUMO pathway with the
18
19 regulation of transcription of *KAI1*, a metastasis suppressor gene [126, 127].
20
21 Naturally occurring mutations in a number of genes have been associated with
22
23 defects in SUMOylation of the mutant proteins, like for example missense mutations
24
25 in the T-box transcription factor TBX22, present in patients with X-linked cleft palate
26
27 (CPX) [128], and missense and nonsense mutations in p63 that disrupt the
28
29 SUMOylation site(s) [55]. In the cases where mutation positions tested were distant
30
31 from the SUMO attachment site(s), it may be that conformational changes caused
32
33 by these single substitutions disrupt the availability of the SUMO attachment site or
34
35 cause mechanical problems that disturb the interactions with the SUMO peptide
36
37 and/or the SUMO-conjugating enzymes. Furthermore, other proteins with a direct
38
39 association to craniofacial defects have been shown to be SUMOylated, such as
40
41 MSX1 and special AT-rich sequence binding protein 2 (SATB2) [44, 55, 56, 129],
42
43 and SUMO modification has been shown to be necessary for their normal function.
44
45 In the case of SATB2, SUMO-1 attachment has been shown to directly regulate its
46
47 activation potential and its localisation into the nucleus [129], while mutations in the
48
49 SUMO acceptor sites of p63 result in a significant increase of the transactivation
50
51 potential of the protein and affect the transcription regulation of its target genes,
52
53 although they do not appear to disturb its nuclear localisation [56]. Mutation of
54
55 SUMO attachment sites for both TBX22 and SATB2 compromise their function,
56
57
58
59
60 while several other SUMOylated proteins have been shown to retain their

1
2
3 transcriptional activity when their SUMOylation sites are disrupted, for example
4
5 LEF1, p53, Msx1 and STAT1 [113, 130–132]. In the case of Msx1, interaction of the
6
7 protein with PIAS1, an enzyme that acts as an E3 ligase in the SUMO modification
8
9 pathway, appears to modulate the function of Msx1 as a transcriptional repressor,
10
11 its ability to bind DNA elements in a target promoter sequence and inhibit terminal
12
13 myocyte differentiation, while no significant functional defects are observed with
14
15 mutations in SUMO attachment sites [133]. This supports the theory that SUMO
16
17 modification can affect target protein function through different mechanisms, and
18
19 hints to the fact that certain proteins that are involved in one signalling cascade may
20
21 share the same SUMO regulatory mechanism.
22
23
24
25
26

27 **9 Conclusions**

28
29
30
31 For most of the SUMO target proteins described so far only a small fraction of the
32
33 total substrate protein present in cells appears to be SUMOylated, and very few
34
35 examples of substrates appear to be modified at a greater percentage; for example
36
37 50% of Ran GTPase-activating protein 1 (RanGAP1) is modified within the cell at
38
39 any given time [134]. The modified substrate may represent the functionally active
40
41 form, at least for a certain part of a biochemical pathway. It has been suggested that
42
43 SUMO modification is a very transient state, where target proteins get modified and
44
45 un-modified perhaps as part of a loop, rather than specific protein molecules staying
46
47 stably modified within a cell. Attachment of SUMO peptides to substrates may
48
49 facilitate a specific function (for example interaction with DNA, other proteins and
50
51 co-factors), and specific peptidases de-conjugate the SUMO molecules from
52
53 substrates when this function is complete, effectively freeing them up inside the cell
54
55 for the next round of modification [135]. In addition, it may also be possible that the
56
57 unmodified proteins have a different role within the cells, besides the one conferred
58
59 on them upon SUMOylation. It is becoming increasingly clear that the nature of such
60

1
2
3 protein modifications is essential for cells to maintain the balance between various
4
5 activities that need be completed, and be able to respond to internal and external
6
7 stimuli in rapidly and efficiently, when time is limited and of great importance. One
8
9 can also imagine that it must be much faster and more energy-efficient for the cell
10
11 when the same protein can fulfil different roles within one or more signalling
12
13 pathways, be ready for alternate protein-protein interactions and translocate to
14
15 various cell parts, only by going through rounds of such transient “on-off”
16
17 modification.

18
19
20 Elucidating the relationship between environmental factors, the SUMO pathway and
21
22 the networks of proteins that are influenced by this post-transcriptional modification
23
24 may be crucial for our further understanding of the signalling cascades that underlie
25
26 complex cell and tissue states, like metabolism, cell death and ultimately, human
27
28 disease.
29
30

31
32
33 *This work was supported by the European Commission Coordination Action*
34
35 *ENINET (contract number LSHM-CT-2005-19063). Dr. Artemisia Andreou is the*
36
37 *recipient of a postdoctoral fellowship from the Bodossaki Foundation.*

38
39 ((Funded by:

- 40 • European Commission Coordination Action ENINET
- 41 • Bodossaki Foundation))

42
43
44
45
46 *The authors have declared no conflict of interest.*
47
48
49

50 51 **10 References**

52
53
54
55 [1] Geiss-Friedlander, R., Melchior, F., Concepts in sumoylation: A decade on.
56
57 *Nat. Rev. Mol. Cell Biol.* 2007, *8*, 947–956.

58
59 [2] Bayer, P., Arndt, A., Metzger, S., Mahajan, R. *et al.*, Structure determination
60 of the small ubiquitin-related modifier SUMO-1. *J. Mol. Biol.* 1998, *280*, 275–286.

- 1
2
3 [3] Jin, C., Shiyanova, T., Shen, Z., Liao, X., Heteronuclear nuclear magnetic
4 resonance assignments, structure and dynamics of SUMO-1, a human ubiquitin-like
5 protein. *Int. J. Biol. Macromol.* 2001, *28*, 227–234.
6
7
8
9
10 [4] Johnson, E. S., Protein modification by SUMO. *Annu. Rev. Biochem.* 2004,
11 *73*, 355–382.
12
13
14 [5] Johnson, E. S., Schwienhorst, I., Dohmen, R. J., Blobel, G., The ubiquitin-
15 like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p
16 heterodimer. *EMBO J.* 1997, *16*, 5509–5519.
17
18
19
20 [6] Huang, H. W., Tsoi, S. C., Sun, Y. H., Li, S. S., Identification and
21 characterization of the SMT3 cDNA and gene encoding ubiquitin-like protein from
22 *Drosophila melanogaster*. *Biochem. Mol. Biol. Int.* 1998, *46*, 775–785.
23
24
25
26 [7] Choudhury, B. K., Li, S. S., Identification and characterization of the SMT3
27 cDNA and gene from nematode *Caenorhabditis elegans*. *Biochem. Biophys. Res.*
28 *Commun.* 1997, *234*, 788–791.
29
30
31
32
33 [8] Bohren, K. M., Nadkarni, V., Song, J. H., Gabbay, K. H., Owerbach, D., A
34 M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat
35 shock transcription factors and is associated with susceptibility to type I diabetes
36 mellitus. *J. Biol. Chem.* 2004, *279*, 27233–27238.
37
38
39
40
41
42 [9] Chen, A., Mannen, H., Li, S. S., Characterization of mouse ubiquitin-like
43 SMT3A and SMT3B cDNAs and gene/pseudogenes. *Biochem. Mol. Biol. Int.* 1998,
44 *46*, 1161–1174.
45
46
47
48
49 [10] Lapenta, V., Chiurazzi, P., van der Spek, P., Pizzuti, A. *et al.*, SMT3A, a
50 human homologue of the *S. cerevisiae* SMT3 gene, maps to chromosome 21qter
51 and defines a novel gene family. *Genomics* 1997, *40*, 362–366.
52
53
54
55 [11] Matunis, M. J., Coutavas, E., Blobel, G., A novel ubiquitin-like modification
56 modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between
57 the cytosol and the nuclear pore complex. *J. Cell Biol.* 1996, *135*, 1457–1470.
58
59
60

- 1
2
3 [12] Bohren, K. M., Gabbay, K. H., Owerbach, D., Affinity chromatography of
4 native SUMO proteins using His-tagged recombinant UBC9 bound to Co²⁺-charged
5 talon resin. *Protein Expr. Purif.* 2007, *54*, 289–294.
6
7
8
9
10 [13] Owerbach, D., McKay, E. M., Yeh, E. T., Gabbay, K. H., Bohren, K. M., A
11 proline-90 residue unique to SUMO-4 prevents maturation and sumoylation.
12 *Biochem. Biophys. Res. Commun.* 2005, *337*, 517–520.
13
14
15 [14] Tatham, M. H., Jaffray, E., Vaughan, O. A., Desterro, J. M. *et al.*, Polymeric
16 chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by
17 SAE1/SAE2 and Ubc9. *J. Biol. Chem.* 2001, *276*, 35368–35374.
18
19
20 [15] Chupreta, S., Holmstrom, S., Subramanian, L., Iniguez-Lluhi, J. A., A small
21 conserved surface in SUMO is the critical structural determinant of its transcriptional
22 inhibitory properties. *Mol. Cell. Biol.* 2005, *25*, 4272–4282.
23
24
25 [16] Song, J., Durrin, L. K., Wilkinson, T. A., Krontiris, T. G., Chen, Y.,
26 Identification of a SUMO-binding motif that recognizes SUMO-modified proteins.
27 *Proc. Natl. Acad. Sci. USA* 2004, *101*, 14373–14378.
28
29
30 [17] Saitoh, H., Hinchev, J., Functional heterogeneity of small ubiquitin-related
31 protein modifiers SUMO-1 versus SUMO-2/3. *J. Biol. Chem.* 2000, *275*, 6252–6258.
32
33
34 [18] Hay, R. T., SUMO: A history of modification. *Mol. Cell* 2005, *18*, 1–12.
35
36 [19] Desterro, J. M., Rodriguez, M. S., Kemp, G. D., Hay, R. T., Identification of
37 the enzyme required for activation of the small ubiquitin-like protein SUMO-1. *J.*
38 *Biol. Chem.* 1999, *274*, 10618–10624.
39
40
41 [20] Okuma, T., Honda, R., Ichikawa, G., Tsumagari, N., Yasuda, H., *In vitro*
42 SUMO-1 modification requires two enzymatic steps, E1 and E2. *Biochem. Biophys.*
43 *Res. Commun.* 1999, *254*, 693–698.
44
45
46 [21] Schwienhorst, I., Johnson, E. S., Dohmen, R. J., SUMO conjugation and
47 deconjugation. *Mol. Gen. Genet.* 2000, *263*, 771–786.
48
49
50 [22] Johnson, E. S., Gupta, A. A., An E3-like factor that promotes SUMO
51 conjugation to the yeast septins. *Cell* 2001, *106*, 735–744.
52
53
54
55
56
57
58
59
60

- 1
2
3 [23] Takahashi, Y., Toh-e, A., Kikuchi, Y., A novel factor required for the
4 SUMO1/Smt3 conjugation of yeast septins. *Gene* 2001, 275, 223–231.
5
6
7 [24] Melchior, F., Schergaut, M., Pichler, A., SUMO: Ligases, isopeptidases and
8 nuclear pores. *Trends Biochem. Sci.* 2003, 28, 612–618.
9
10 [25] Mikolajczyk, J., Drag, M., Bekes, M., Cao, J. T. *et al.*, Small ubiquitin-related
11 modifier (SUMO)-specific proteases: Profiling the specificities and activities of
12 human SENPs. *J. Biol. Chem.* 2007, 282, 26217–26224.
13
14 [26] Azuma, Y., Tan, S. H., Cavenagh, M. M., Ainsztein, A. M. *et al.*, Expression
15 and regulation of the mammalian SUMO-1 E1 enzyme. *FASEB J.* 2001, 15, 1825–
16 1827.
17
18 [27] Bailey, D., O'Hare, P., Characterization of the localization and proteolytic
19 activity of the SUMO-specific protease, SENP1. *J. Biol. Chem.* 2004, 279, 692–703.
20
21 [28] Mukhopadhyay, D., Dasso, M., Modification in reverse: The SUMO
22 proteases. *Trends Biochem. Sci.* 2007, 32, 286–295.
23
24 [29] Bailey, D., O'Hare, P., Herpes simplex virus 1 ICP0 co-localizes with a
25 SUMO-specific protease. *J. Gen. Virol.* 2002, 83, 2951–2964.
26
27 [30] Gong, L., Millas, S., Maul, G. G., Yeh, E. T., Differential regulation of
28 sentrinized proteins by a novel sentrin-specific protease. *J. Biol. Chem.* 2000, 275,
29 3355–3359.
30
31 [31] Hang, J., Dasso, M., Association of the human SUMO-1 protease SENP2
32 with the nuclear pore. *J. Biol. Chem.* 2002, 277, 19961–19966.
33
34 [32] Gong, L., Yeh, E. T., Characterization of a family of nucleolar SUMO-specific
35 proteases with preference for SUMO-2 or SUMO-3. *J. Biol. Chem.* 2006, 281,
36 15869–15877.
37
38 [33] Kim, K. I., Baek, S. H., Jeon, Y. J., Nishimori, S. *et al.*, A new SUMO-1-
39 specific protease, SUSP1, that is highly expressed in reproductive organs. *J. Biol.*
40 *Chem.* 2000, 275, 14102–14106.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [34] Mukhopadhyay, D., Ayaydin, F., Kolli, N., Tan, S. H. *et al.*, SUSP1
4 antagonizes formation of highly SUMO2/3-conjugated species. *J. Cell Biol.* 2006,
5 174, 939–949.
6
7
8
9 [35] Braschi, E., Zunino, R., McBride, H. M., MAPL is a new mitochondrial SUMO
10 E3 ligase that regulates mitochondrial fission. *EMBO Rep.* 2009, 10, 748–754.
11
12 [36] Martin, S., Wilkinson, K. A., Nishimune, A., Henley, J. M., Emerging
13 extranuclear roles of protein SUMOylation in neuronal function and dysfunction. *Nat.*
14 *Rev. Neurosci.* 2007, 8, 948–959.
15
16 [37] Benson, M. D., Li, Q. J., Kieckhafer, K., Dudek, D. *et al.*, SUMO modification
17 regulates inactivation of the voltage-gated potassium channel Kv1.5. *Proc. Natl.*
18 *Acad. Sci. USA* 2007, 104, 1805–1810.
19
20 [38] Ayaydin, F., Dasso, M., Distinct *in vivo* dynamics of vertebrate SUMO
21 paralogues. *Mol. Biol. Cell* 2004, 15, 5208–5218.
22
23 [39] Minty, A., Dumont, X., Kaghad, M., Caput, D., Covalent modification of
24 p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-
25 interacting proteins and a SUMO-1 interaction motif. *J. Biol. Chem.* 2000, 275,
26 36316–36323.
27
28 [40] Rodriguez, M. S., Dargemont, C., Hay, R. T., SUMO-1 conjugation *in vivo*
29 requires both a consensus modification motif and nuclear targeting. *J. Biol. Chem.*
30 2001, 276, 12654–12659.
31
32 [41] Iniguez-Lluhi, J. A., Pearce, D., A common motif within the negative
33 regulatory regions of multiple factors inhibits their transcriptional synergy. *Mol. Cell.*
34 *Biol.* 2000, 20, 6040–6050.
35
36 [42] Poukka, H., Karvonen, U., Yoshikawa, N., Tanaka, H. *et al.*, The RING finger
37 protein SNURF modulates nuclear trafficking of the androgen receptor. *J. Cell Sci.*
38 2000, 113, 2991–3001.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [43] Yang, S. H., Galanis, A., Witty, J., Sharrocks, A. D., An extended consensus
4 motif enhances the specificity of substrate modification by SUMO. *EMBO J.* 2006,
5 25, 5083–5093.
6
7
8
9
10 [44] Gupta, V., Bei, M., Modification of Msx1 by SUMO-1. *Biochem. Biophys.*
11 *Res. Commun.* 2006, 345, 74–77.
12
13 [45] Hecker, C. M., Rabiller, M., Haglund, K., Bayer, P., Dikic, I., Specification of
14 SUMO1- and SUMO2-interacting motifs. *J. Biol. Chem.* 2006, 281, 16117–16127.
15
16
17 [46] Rosendorff, A., Sakakibara, S., Lu, S., Kieff, E. *et al.*, NXP-2 association with
18 SUMO-2 depends on lysines required for transcriptional repression. *Proc. Natl.*
19 *Acad. Sci. USA* 2006, 103, 5308–5313.
20
21
22
23 [47] Hilgarth, R. S., Hong, Y., Park-Sarge, O. K., Sarge, K. D., Insights into the
24 regulation of heat shock transcription factor 1 SUMO-1 modification. *Biochem.*
25 *Biophys. Res. Commun.* 2003, 303, 196–200.
26
27
28
29 [48] Hietakangas, V., Ahlskog, J. K., Jakobsson, A. M., Hellesuo, M. *et al.*,
30 Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO
31 modification of heat shock factor 1. *Mol. Cell. Biol.* 2003, 23, 2953–2968.
32
33
34 [49] Hietakangas, V., Anckar, J., Blomster, H. A., Fujimoto, M. *et al.*, PDSM, a
35 motif for phosphorylation-dependent SUMO modification. *Proc. Natl. Acad. Sci. USA*
36 2006, 103, 45–50.
37
38
39 [50] Girdwood, D., Bumpass, D., Vaughan, O. A., Thain, A. *et al.*, P300
40 transcriptional repression is mediated by SUMO modification. *Mol. Cell* 2003, 11,
41 1043–1054.
42
43
44
45 [51] Yang, S. H., Sharrocks, A. D., SUMO promotes HDAC-mediated
46 transcriptional repression. *Mol. Cell* 2004, 13, 611–617.
47
48
49 [52] Gill, G., Something about SUMO inhibits transcription. *Curr. Opin. Genet.*
50 *Dev.* 2005, 15, 536–541.
51
52
53 [53] Stankovic-Valentin, N., Deltour, S., Seeler, J., Pinte, S. *et al.*, An
54 acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved
55
56
57
58
59
60

1
2
3 psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression
4 activity. *Mol. Cell. Biol.* 2007, 27, 2661–2675.

5
6
7 [54] Shii, Y., Eisenman, R. N., Histone sumoylation is associated with
8 transcriptional repression. *Proc. Natl. Acad. Sci. USA* 2003, 100, 13225–13230.

9
10 [55] Ghioni, P., D'Alessandra, Y., Mansueto, G., Jaffray, E. *et al.*, The protein
11 stability and transcriptional activity of p63alpha are regulated by SUMO-1
12 conjugation. *Cell Cycle* 2005, 4, 183–190.

13
14 [56] Huang, Y. P., Wu, G., Guo, Z., Osada, M. *et al.*, Altered sumoylation of
15 p63alpha contributes to the split-hand/foot malformation phenotype. *Cell Cycle*
16 2004, 3, 1587–1596.

17
18 [57] Long, J., Wang, G., He, D., Liu, F., Repression of Smad4 transcriptional
19 activity by SUMO modification. *Biochem. J.* 2004, 379, 23–29.

20
21 [58] de The, H., Lavau, C., Marchio, A., Chomienne, C. *et al.*, The PML-RAR
22 alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic
23 leukemia encodes a functionally altered RAR. *Cell* 1991, 66, 675–684.

24
25 [59] Goddard, A. D., Borrow, J., Freemont, P. S., Solomon, E., Characterization
26 of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia.
27 *Science* 1991, 254, 1371–1374.

28
29 [60] Kakizuka, A., Miller, W. H., Jr., Umesono, K., Warrell, R. P. Jr. *et al.*,
30 Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses
31 RAR alpha with a novel putative transcription factor, PML. *Cell* 1991, 66, 663–674.

32
33 [61] Kastner, P., Perez, A., Lutz, Y., Rochette-Egly, C. *et al.*, [Fusion proteins
34 between PML and alpha-RAR in acute promyelocytic leukemia]. *C. R. Seances Soc.*
35 *Biol. Fil.* 1991, 185, 391–401.

36
37 [62] Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R. *et al.*,
38 Arsenic degrades PML or PML-RARalpha through a SUMO-triggered
39 RNF4/ubiquitin-mediated pathway. *Nat. Cell Biol.* 2008, 10, 547–555.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [63] Tatham, M. H., Geoffroy, M. C., Shen, L., Plechanovova, A. *et al.*, RNF4 is a
4 poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML
5 degradation. *Nat. Cell Biol.* 2008, 10, 538–546.
6
7
8
9 [64] Schmidt, D., Muller, S., Members of the PIAS family act as SUMO ligases for
10 c-Jun and p53 and repress p53 activity. *Proc. Natl. Acad. Sci. USA* 2002, 99, 2872–
11 2877.
12
13 [65] Garcia-Dominguez, M., Reyes, J. C., SUMO association with repressor
14 complexes, emerging routes for transcriptional control. *Biochim. Biophys. Acta*
15 2009, 1789, 451–459.
16
17 [66] Butt, T. R., Edavettal, S. C., Hall, J. P., Mattern, M. R., SUMO fusion
18 technology for difficult-to-express proteins. *Protein Expr. Purif.* 2005, 43, 1–9.
19
20 [67] Malakhov, M. P., Mattern, M. R., Malakhova, O. A., Drinker, M. *et al.*, SUMO
21 fusions and SUMO-specific protease for efficient expression and purification of
22 proteins. *J. Struct. Funct. Genomics* 2004, 5, 75–86.
23
24 [68] Marblestone, J. G., Edavettal, S. C., Lim, Y., Lim, P. *et al.*, Comparison of
25 SUMO fusion technology with traditional gene fusion systems: Enhanced expression
26 and solubility with SUMO. *Protein Sci.* 2006, 15, 182–189.
27
28 [69] Zuo, X., Li, S., Hall, J., Mattern, M. R. *et al.*, Enhanced expression and
29 purification of membrane proteins by SUMO fusion in *Escherichia coli*. *J. Struct.*
30 *Funct. Genomics* 2005, 6, 103–111.
31
32 [70] Lee, C. D., Sun, H. C., Hu, S. M., Chiu, C. F. *et al.*, An improved SUMO
33 fusion protein system for effective production of native proteins. *Protein Sci.* 2008,
34 17, 1241–1248.
35
36 [71] Liu, L., Spurrier, J., Butt, T. R., Strickler, J. E., Enhanced protein expression
37 in the baculovirus/insect cell system using engineered SUMO fusions. *Protein Expr.*
38 *Purif.* 2008, 62, 21–28.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [72] Peroutka, R. J., Elshourbagy, N., Piech, T., Butt, T. R., Enhanced protein
4 expression in mammalian cells using engineered SUMO fusions: Secreted
5 phospholipase A2. *Protein Sci.* 2008, *17*, 1586–1595.
6
7
8
9
10 [73] Leavenworth, J. W., Ma, X., Mo, Y. Y., Pauza, M. E., SUMO conjugation
11 contributes to immune deviation in nonobese diabetic mice by suppressing c-Maf
12 transactivation of IL-4. *J. Immunol.* 2009, *183*, 1110–1119.
13
14
15
16 [74] Wang, C. Y., She, J. X., SUMO4 and its role in type 1 diabetes
17 pathogenesis. *Diabetes Metab. Res. Rev.* 2008, *24*, 93–102.
18
19
20 [75] Woo, C. H., Shishido, T., McClain, C., Lim, J. H. *et al.*, Extracellular signal-
21 regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory
22 response and endothelial nitric oxide synthase expression in endothelial cells. *Circ.*
23 *Res.* 2008, *102*, 538–545.
24
25
26
27 [76] Dorval, V., Fraser, P. E., SUMO on the road to neurodegeneration. *Biochim.*
28 *Biophys. Acta* 2007, *1773*, 694–706.
29
30
31 [77] Ehninger, A., Mziaut, H., Solimena, M., Emerging role of SUMO in
32 pancreatic beta-cells. *Horm. Metab. Res.* 2007, *39*, 658–664.
33
34
35 [78] Kim, K. I., Baek, S. H., Small ubiquitin-like modifiers in cellular malignancy
36 and metastasis. *Int. Rev. Cell Mol. Biol.* 2009, *273*, 265–311.
37
38
39 [79] Li, M., Guo, D., Isales, C. M., Eizirik, D. L. *et al.*, SUMO wrestling with type 1
40 diabetes. *J. Mol. Med.* 2005, *83*, 504–513.
41
42
43 [80] Dimmer, K. S., Scorrano, L., (De)constructing mitochondria: What for?
44 *Physiology (Bethesda)* 2006, *21*, 233–241.
45
46
47 [81] Bossy-Wetzell, E., Barsoum, M. J., Godzik, A., Schwarzenbacher, R., Lipton,
48 S. A., Mitochondrial fission in apoptosis, neurodegeneration and aging. *Curr. Opin.*
49 *Cell Biol.* 2003, *15*, 706–716.
50
51
52 [82] Hales, K. G., Fuller, M. T., Developmentally regulated mitochondrial fusion
53 mediated by a conserved, novel, predicted GTPase. *Cell* 1997, *90*, 121–129.
54
55
56
57
58
59
60

- 1
2
3 [83] Desagher, S., Martinou, J. C., Mitochondria as the central control point of
4 apoptosis. *Trends Cell Biol.* 2000, *10*, 369–377.
5
6
7 [84] Harder, Z., Zunino, R., McBride, H., Sumo1 conjugates mitochondrial
8 substrates and participates in mitochondrial fission. *Curr. Biol.* 2004, *14*, 340–345.
9
10 [85] Figueroa-Romero, C., Iniguez-Lluh, J. A., Stadler, J., Chang, C. R. *et al.*,
11 SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple
12 nonconsensus sites within the B domain and is linked to its activity cycle. *FASEB J.*
13 2009.
14
15 [86] Zunino, R., Schauss, A., Rippstein, P., Andrade-Navarro, M., McBride, H.
16 M., The SUMO protease SENP5 is required to maintain mitochondrial morphology
17 and function. *J. Cell Sci.* 2007, *120*, 1178–1188.
18
19 [87] Neuspiel, M., Schauss, A. C., Braschi, E., Zunino, R. *et al.*, Cargo-selected
20 transport from the mitochondria to peroxisomes is mediated by vesicular carriers.
21 *Curr. Biol.* 2008, *18*, 102–108.
22
23 [88] Bossis, G., Melchior, F., Regulation of SUMOylation by reversible oxidation
24 of SUMO conjugating enzymes. *Mol. Cell* 2006, *21*, 349–357.
25
26 [89] Boggio, R., Chiocca, S., Viruses and sumoylation: Recent highlights. *Curr.*
27 *Opin. Microbiol.* 2006, *9*, 430–436.
28
29 [90] Kurepa, J., Walker, J. M., Smalle, J., Gosink, M. M. *et al.*, The small
30 ubiquitin-like modifier (SUMO) protein modification system in *Arabidopsis*.
31 Accumulation of SUMO1 and -2 conjugates is increased by stress. *J. Biol. Chem.*
32 2003, *278*, 6862–6872.
33
34 [91] Sramko, M., Markus, J., Kabat, J., Wolff, L., Bies, J., Stress-induced
35 inactivation of the c-Myb transcription factor through conjugation of SUMO-2/3
36 proteins. *J. Biol. Chem.* 2006, *281*, 40065–40075.
37
38 [92] Zhou, W., Ryan, J. J., Zhou, H., Global analyses of sumoylated proteins in
39 *Saccharomyces cerevisiae*. Induction of protein sumoylation by cellular stresses. *J.*
40 *Biol. Chem.* 2004, *279*, 32262–32268.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [93] Hong, Y., Rogers, R., Matunis, M. J., Mayhew, C. N. *et al.*, Regulation of
4 heat shock transcription factor 1 by stress-induced SUMO-1 modification. *J. Biol.*
5 *Chem.* 2001, *276*, 40263–40267.
6
7
8
9
10 [94] Manza, L. L., Codreanu, S. G., Stamer, S. L., Smith, D. L. *et al.*, Global shifts
11 in protein sumoylation in response to electrophile and oxidative stress. *Chem. Res.*
12 *Toxicol.* 2004, *17*, 1706–1715.
13
14
15
16 [95] Golebiowski, F., Matic, I., Tatham, M. H., Cole, C. *et al.*, System-wide
17 changes to SUMO modifications in response to heat shock. *Sci. Signal.* 2009, *2*,
18 ra24.
19
20
21
22 [96] Comerford, K. M., Leonard, M. O., Karhausen, J., Carey, R. *et al.*, Small
23 ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent
24 responses to hypoxia. *Proc. Natl. Acad. Sci. USA* 2003, *100*, 986–991.
25
26
27
28 [97] Bossis, G., Melchior, F., SUMO: Regulating the regulator. *Cell Div.* 2006, *1*,
29 13.
30
31
32
33 [98] Li, T., Santockyte, R., Shen, R.F., Teckle, E. *et al.*, Expression of SUMO-2/3
34 induced senescence through p53- and pRB-mediated pathways. *J. Biol. Chem.*
35 2006, *281*, 36221–36227.
36
37
38
39 [99] Finkel, T., Oxidant signals and oxidative stress. *Curr. Opin. Cell Biol.* 2003,
40 *15*, 247–254.
41
42
43
44 [100] Boggio, R., Colombo, R., Hay, R. T., Draetta, G. F., Chiocca, S., A
45 mechanism for inhibiting the SUMO pathway. *Mol. Cell* 2004, *16*, 549–561.
46
47
48
49 [101] Muller, S., Dejean, A., Viral immediate-early proteins abrogate the
50 modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body
51 disruption. *J. Virol.* 1999, *73*, 5137–5143.
52
53
54
55 [102] Li, S. J., Hochstrasser, M., A new protease required for cell-cycle
56 progression in yeast. *Nature* 1999, *398*, 246–251.
57
58
59
60 [103] Bischof, O., and DEjean, A., SUMO is growing senescent. *Cell Cycle* 2007,
6, 677–681.

- 1
2
3 [104] Akar, C. A., Feinstein, D. L., Modulation of inducible nitric oxide synthase
4 expression by sumoylation. *J. Neuroinflammation* 2009, 6, 12.
5
6
7 [105] Li, T., Evdokimov, E., Shen, R. F., Chao, C. C. *et al.*, Sumoylation of
8 heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore
9 complex proteins: A proteomic analysis. *Proc. Natl. Acad. Sci. USA* 2004, 101,
10 8551–8556.
11
12 [106] Campisi, J., Senescent cells, tumor suppression and organismal aging: Good
13 citizens, bad neighbors. *Cell* 2005, 120, 513–522.
14
15 [107] Okada, H., Mak, T. W., Pathways of apoptotic and non-apoptotic death in
16 tumour cells. *Nat. Rev. Cancer* 2004, 4, 592–603.
17
18 [108] Ben-Porath, I. a. W., R.A., When cells get stressed: An integrative view of
19 cellular senescence. *J. Clin. Invest.* 2004, 113, 8–13.
20
21 [109] Hickman, E. S., Moroni, M.C., Helin, K., The role of p53 and pRB in
22 apoptosis and cancer. *Curr. Opin. Genet. Dev.* 2002, 12, 60–66.
23
24 [110] Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P. *et al.*, Activation of p53
25 by conjugation to the ubiquitin-like protein SUMO-1. *EMBO J.* 1999, 18, 6462–6471.
26
27 [111] Ledl, A., Schmidt, D., and Muller, S., Viral oncoproteins E1A and E7 and
28 cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor
29 suppressor. *Oncogene* 2005, 24, 3810–3818.
30
31 [112] Muller, S., Berger, M., Lehembre, F., Seeler, J. S. *et al.*, c-Jun and p53
32 activity is modulated by SUMO-1 modification. *J. Biol. Chem.* 2000, 275, 13321–
33 13329.
34
35 [113] Rodriguez, M., Desterro, J.M., Lain, S., Midgley, C.A. *et al.*, SUMO-1
36 modification activates the transcriptional response of p53. *EMBO J.* 1999, 18, 6455–
37 6461.
38
39 [114] Bischof, O., Schwamborn, K., Martin, N., Werner, A. *et al.*, The E3 SUMO
40 ligase PIASy is a regulator of cellular senescence and apoptosis. *Mol. Cell* 2006, 22,
41 783–794.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [115] Sugrue, M. M., Shin, D.Y., Lee, S.W., Aaronson, S.A., Wild-type p53 triggers
4 a rapid senescence program in human tumor cells lacking functional p53. *Proc. Natl.*
5 *Acad. Sci. USA* 1997, *97*, 9648–9653.
6
7
8
9 [116] Schmidt, D., Müller, S., PIAS/SUMO: New partners in transcriptional
10 regulation. *Cell. Mol. Life Sci.* 2003, *60*, 2561–2574.
11
12 [117] Uchimura, Y., Ichimura, T., Uwada, J., Tachibana, T. *et al.*, Involvement of
13 SUMO modification in MBD1- and MCAF1-mediated heterochromatin formation. *J.*
14 *Biol. Chem.* 2006, *281*, 23180–23190.
15
16 [118] Nathan, D., Ingvarsdottir, K., Sterner, D. E., Bylebyl, G. R. *et al.*, Histone
17 sumoylation is a negative regulator in *Saccharomyces cerevisiae* and shown
18 dynamic interplay with positive-acting histone modifications. *Genes Dev.* 2006, *20*,
19 966–976.
20
21 [119] Yates, K. E., Korbel, G. A., Shtutman, M., Roninson, I. B., DiMaio, D.,
22 Repression of the SUMO-specific protease Senp1 induces p53-dependent
23 premature senescence in normal human fibroblasts. *Aging Cell* 2008, *7*, 609–621.
24
25 [120] Yang, W., Sheng, H., Warner, D. S., Paschen, W., Transient global cerebral
26 ischemia induces a massive increase in protein sumoylation. *J. Cereb. Blood Flow*
27 *Metab.* 2008, *28*, 269–279.
28
29 [121] Subramaniam, S., Sixt, K. M., Barrow, R., Snyder, S. H., Rhes, a striatal
30 specific protein, mediates mutant-huntingtin cytotoxicity. *Science* 2009, *324*, 1327–
31 1330.
32
33 [122] Falk, J. D., Vargiu, P., Foye, P. E., Usui, H. *et al.*, Rhes: A striatal-specific
34 Ras homolog related to Dexas1. *J. Neurosci. Res.* 1999, *57*, 782–788.
35
36 [123] Mukherjee, S., Thomas, M., Dadgar, N., Lieberman, A. P., Iniguez-Lluhi, J.
37 A., Small ubiquitin-like modifier (SUMO) modification of the androgen receptor
38 attenuates polyglutamine-mediated aggregation. *J. Biol. Chem.* 2009, *284*, 21296–
39 21306.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [124] Um, J. W., Chung, K. C., Functional modulation of parkin through physical
4 interaction with SUMO-1. *J. Neurosci. Res.* 2006, *84*, 1543–1554.
5
6
7 [125] Wu, F., Mo, Y., Ubiquitin-like protein modifications in prostate and breast
8 cancer. *Front. Biosci.* 2007, *12*, 700–711.
9
10 [126] Baek, S. H., Ohgi, K. A., Rose, D. W., Koo, E. H. *et al.*, Exchange of N-CoR
11 corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB
12 and beta-amyloid precursor protein. *Cell* 2002, *110*, 55–67.
13
14 [127] Kim, J. H., Choi, H. J., Kim, B., Kim, M. H. *et al.*, Roles of sumoylation of a
15 reptin chromatin-remodelling complex in cancer metastasis. *Nat. Cell Biol.* 2006, *8*,
16 631–639.
17
18 [128] Andreou, A. M., Pauws, E., Jones, M. C., Singh, M. K. *et al.*, TBX22
19 missense mutations found in patients with X-linked cleft palate affect DNA binding,
20 sumoylation, and transcriptional repression. *Am. J. Hum. Genet.* 2007, *81*, 700–712.
21
22 [129] Dobrev, G., Dambacher, J., Grosschedl, R., SUMO modification of a novel
23 MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression.
24
25 *Genes Dev.* 2003, *17*, 3048–3061.
26
27 [130] Lee, M. H., Lee, S. W., Lee, E. J., Choi, S. J. *et al.*, SUMO-specific protease
28 SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. *Nat. Cell*
29 *Biol.* 2006, *8*, 1424–1431.
30
31 [131] Rogers, R. S., Horvath, C. M., Matunis, M. J., SUMO modification of STAT1
32 and its role in PIAS-mediated inhibition of gene activation. *J. Biol. Chem.* 2003, *278*,
33 30091–30097.
34
35 [132] Sachdev, S., Bruhn, L., Sieber, H., Pichler, A. *et al.*, PIASy, a nuclear matrix-
36 associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear
37 bodies. *Genes Dev.* 2001, *15*, 3088–3103.
38
39 [133] Lee, H., Quinn, J. C., Prasanth, K. V., Swiss, V. A. *et al.*, PIAS1 confers
40 DNA-binding specificity on the Msx1 homeoprotein. *Genes Dev.* 2006, *20*, 784–794.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 [134] Mahajan, R., Delphin, C., Guan, T., Gerace, L., Melchior, F., A small
4 ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore
5 complex protein RanBP2. *Cell* 1997, *88*, 97–107.


6
7
8
9 [135] Hardeland, U., Steinacher, R., Jiricny, J., Schar, P., Modification of the
10 human thymine-DNA glycosylase by ubiquitin-like proteins facilitates enzymatic
11 turnover. *EMBO J.* 2002, *21*, 1456–1464.
12
13
14
15
16
17

18 **Figure 1.** Brief schematic representation of the SUMO pathway. SUMO is
19 conjugated to and de-conjugation from target proteins in a series of steps that
20 involve enzymes corresponding to those of the ubiquitin pathway. Mature SUMO is
21 produced from the precursor protein, it is then activated by E1 enzyme, and passed
22 on, through subsequent thioester bonds, from the E2-conjugating enzyme Ubc9
23 onto the substrate protein. Release of SUMO from the complex is catalysed by a
24 SUMO hydrolase of the SENP family.
25
26
27
28
29
30
31
32

33 **Figure 2.** Components of SUMOylation in stress-response pathways leading to
34 cellular senescence and ageing. Upon intra- or extracellular stress, the
35 SUMOylation cycle of p53 is crucial to downstream signalling cascades that lead to
36 senescence and ageing. Disturbances at both the SUMO conjugation and de-
37 conjugation steps can impede the normal function of these pathways and block the
38 onset of senescence. SUMOylation of pRB can influence the decision of the cell to
39 undergo senescence or apoptosis. The SUMO E3 ligase PIASy and SUMO
40 proteases of the SENP family also appear to have important roles in these
41 pathways.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ((authors CVs))
4

5 Nektarios Tavernarakis is Research Director (Professor) at the Institute
6 of Molecular Biology and Biotechnology, in Heraklion, Crete, Greece, heading
7 the *Caenorhabditis elegans* molecular genetics laboratory. He earned his
8 Ph.D. degree at the University of Crete, studying gene expression regulation
9 in yeast, and was trained in *C. elegans* genetics and molecular biology at
10 Rutgers University, New Jersey, USA. His research focuses on studies of
11 neuronal function and dysfunction, using the nematode *C. elegans*
12 as a model organism. His main interests are the molecular mechanisms of
13 necrotic cell death in neurodegeneration and senescent decline, the
14 molecular mechanisms of sensory transduction and integration by the nervous
15 system, the interplay between cellular metabolism and ageing, and the
16 development of novel genetic tools for *C. elegans* research. He is recipient of a
17 European Research Council (ERC) Advanced Investigator grant
18 award, a European Molecular Biology Organization (EMBO) Young Investigator
19 award, an International Human Frontier in Science Program Organization
20 (HFSP) long-term award, the Bodossaki Foundation Scientific Prize for
21 Medicine and Biology, the Alexander von Humboldt Foundation, Friedrich
22 Wilhelm Bessel research award, and is member of EMBO.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Andreou & Tavernarakis, Fig. 1

254x190mm (300 x 300 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



801x601mm (72 x 72 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



225x169mm (72 x 72 DPI)

review